J&J hits $25.3bn Q2 sales, eyes $100bn milestone; Eli Lilly bets $3.8bn on psychedelics

Johnson & Johnson, operating across more than 60 countries with over 140,000 employees, delivered Q2 2026 results that reinforced its position at the forefront of pharmaceutical development. Reported quarterly sales reached US$25.3bn, reflecting 6.6% growth and momentum across its Innovative Medicine and MedTech businesses. The company has now raised its 2026 annual sales guidance to US$101.1bn, up from US$100.8bn, positioning it to achieve the historic milestone of US$100bn in annual revenue for the first time.

Elsewhere, Eli Lilly announced it is set to acquire AtaiBeckley for up to US$3.8bn, marking the company's first entry into psychedelic-based drug discovery. The move targets treatment-resistant depression, a condition that persists even after multiple standard treatments have failed. Carole Ho, Executive Vice President at Eli Lilly and President at Lilly Neuroscience, stated: "Treatment-resistant depression persists even after multiple treatments have failed. Millions of people are still searching for relief and desperately need a therapy that works. Advancing AtaiBeckley's investigational therapies gives us a real chance to change that." The deal is positioned as a significant step in developing next-generation mental health treatments within Eli Lilly's expanding neuroscience pipeline.

Bristol Myers Squibb is scaling its AI infrastructure for drug discovery by deploying a second NVIDIA-powered system that the company describes as the "most powerful AI factory in life sciences." The new system will utilize an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems and will deliver up to ten times greater performance per megawatt than BMS's predecessor system. BMS already possesses one of the life science industry's most powerful AI systems, powered by advanced NVIDIA technology, to support its wide-ranging research and development programmes. The new infrastructure is positioned as the life sciences industry's most powerful and energy-efficient privately owned NVIDIA infrastructure.

In related news, Wood Mackenzie research examined how declining birth rates could reshape energy demand patterns over coming decades, with implications for public health systems and their resource availability. According to the UN's low fertility scenario modeled by Wood Mackenzie, global population would peak at 8.9 billion in 2053 before falling to 7 billion by century's end—contrasting with the UN's central projection of 10 billion by 2060 and a high fertility scenario reaching 12.6 billion by 2100. These divergent population trajectories carry implications for health infrastructure planning and the energy systems supporting hospitals, medical facilities, and pharmaceutical production. The World Economic Forum warned against repeating mistakes from earlier digital transformation waves, citing the rollout of electronic health records (EHRs), which promised better coordination and improved clinical decision-making but initially contributed to growing administrative workloads, forcing doctors to spend more time documenting care than delivering it. The WEF argues that AI, deployed in a background role removing friction from healthcare delivery, must prioritize clinician-patient interaction time rather than take centre stage, with the global AI healthcare market on track to reach US$491bn by 2032.

Pharma's largest players are responding to mounting R&D pressures through parallel strategies: consolidating market position via pricing and portfolio breadth, exploring emerging science in adjacent therapeutic areas, and automating discovery through AI infrastructure. J&J's guidance lift—modest on a percentage basis—matters because it anchors a US$100bn milestone in absolute terms, reflecting the scale concentration in the industry. Eli Lilly's US$3.8bn outlay on psychedelic-assisted treatment represents a calculated bet on a mechanism class still early in clinical validation; the company frames it as addressing an unmet need (millions with treatment-resistant depression searching for relief), but the risk lies in whether early-stage investigational therapies will survive phase-level development. BMS's infrastructure investment signals that computational efficiency is now a first-order competitive variable—tenfold performance-per-megawatt gains translate directly to cost per candidate or throughput per unit energy, altering the unit economics of discovery.

No comments yet. Be the first to share your thoughts!